Table 1.
demographic and baseline characteristics of the patients
| CHARACTERISTIC | NUMBER |
|---|---|
| Sex | |
| Male | 81(60.0%) |
| Female | 54 (40.0%) |
| Age | 45.60 ± 1.0 year |
| Dialysis duration | 6.45 (5.0,9.0) year |
| Dialysis modality | |
| PD | 12 (8.9%) |
| HD | 121 (89.6%) |
| ESRD without dialysis | 2 (1.5%) |
| Primary disease | |
| CGN | 108 (80%) |
| Polycystic kidney | 10 (7.4%) |
| Hypertensive nephropathy | 5 (3.7%) |
| Diabetic nephropathy | 4 (3.0%) |
| Others | 8 (5.9%) |
| The number of parathyroid gland | |
| <4 | 16 (11.9%) |
| ≥ 4 | 119 (88.1%) |
| Blood pressure | |
| Pre-PTX systolic pressure (mmHg) | 139.4 ± 22.8 |
| Pre-PTX diastolic pressure (mmHg) | 88.6 ± 15.4 |
| 1-year post-PTX systolic pressure (mmHg) | 144.5 ± 23.5 |
| 1-year post-PTX diastolic pressure (mmHg) | 80.1 ± 13.3 |
| cardiovascular drugs used during the follow-up | |
| ACEI | 5 (3.7%) |
| ARBs | 30 (22.2%) |
| calcium blockers | 50 (37.0%) |
| cardiotonics | 1 (0.7%) |
| β-blockers | 48 (35.6%) |
| isosorbide mononitrate | 11 (8.1%) |
| trimetazidine | 8 (5.9%) |
PD peritoneal dialysis, HD: hemodialysis, ESRD End Stage Renal Disease, CGN chronic glomerulonephritis, ACEI angiotensin-converting enzyme inhibitors, ARBs angiotensin receptor blockers